Aug. 11 at 2:23 AM
$LMDX $RHHBY $FCN $NDAQ
There are multiple red flags suggesting asset undervaluation, insider enrichment, and improper transfers that may be actionable through regulatory complaints or legal action.
Key points:
1. Roche acquired LMDX’s core assets (including the TB test) for far below fair value, without transparent independent valuation.
2. Subsidiaries and technology — including Invita Technologies, SureSensors Limited, and LumiraDx Colombia — were moved or sold at questionable prices before dissolution.
3. Former CEO Ron Zwanziger resigned citing a “conflict of interest” and later became active in ElectraDx, which raised
$14M while LMDX was still operating.
4. Executives, including Veronique Ameye, received post-sale roles and bonuses during insolvency.
5. A new patent was awarded to LMDX during liquidation, raising questions about IP diversion.
6. Gates Foundation retained rights to TB technology, possibly removing value from shareholders.
